Cullgen
Phase 1GYRE THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE CULLGEN TO GAIN TARGETED PROTEIN DEGRADATION PLATFORM AND PIPELINE
Founded
2018
Focus
Small Molecules
About
GYRE THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE CULLGEN TO GAIN TARGETED PROTEIN DEGRADATION PLATFORM AND PIPELINE
Funding History
3Total raised: $125M
Series C$65MOrbiMedJun 15, 2022
Series B$45MUndisclosedJun 15, 2020
Series A$15MUndisclosedJun 15, 2018
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile